Therapeutic concepts of brachytherapy/megavoltage in sequence for pharyngeal wall cancers. Results of integrated dose therapy.
This is a follow-up report on lateral, posterior oro-, hypopharyngeal wall cancer treatment based on a new therapeutic concept. Ir-192 or I-125 brachytherapy and craniocervical megavoltage irradiation are effective with improved local control and NED (no evidence of disease) survival rates. Local failure rate is 14% and actuarial survival (NED) is 82% at 5 years in 14 patients treated thus far.
D000206:Actuarial Analysis; D000368:Aged; D001918:Brachytherapy / Q000009:adverse effects; D005260:Female; D006801:Humans; D007013:Hypopharynx / Q000473:pathology; D007457:Iodine Radioisotopes / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009960:Oropharynx / Q000473:pathology; D010610:Pharyngeal Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy
D007457:Iodine Radioisotopes